Literature DB >> 20887775

Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo.

Shankar J Chinta1, Jyothi K Mallajosyula, Anand Rane, Julie K Andersen.   

Abstract

Alpha-synuclein is the major protein component of Lewy bodies, a cardinal pathological feature of the degenerating Parkinsonian brain. Alpha-synuclein has been reported to be able to intercalate into membranes via formation of an alpha-helical structure at its N-terminal end. Recent in vitro studies from various laboratories have demonstrated that α-synuclein can physically associate with mitochondria and interfere with mitochondrial function. α-Syn predominantly associates with the inner mitochondrial membrane, where it can apparently interact with complex I resulting in reduced mitochondrial complex I activity and increased free radical production. However, the effect of in vivo α-synuclein accumulation within dopaminergic neurons on mitochondrial function has not been thoroughly studied. Examination of transgenic animals which overexpress the familial mutant A53T form of the protein selectively within dopaminergic neurons reveals that A53T localizes to the mitochondrial membranes as monomers and oligomers particularly under conditions of proteasomal inhibitory stress, and that this localization coincides with a selective age-related mitochondrial complex I inhibition and decreased substrate-specific respiration along with increases in mitochondrial autophagy (mitophagy).
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20887775      PMCID: PMC2967673          DOI: 10.1016/j.neulet.2010.09.061

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

1.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.

Authors:  Kevin St P McNaught; Daniel P Perl; Anna-Liisa Brownell; C Warren Olanow
Journal:  Ann Neurol       Date:  2004-07       Impact factor: 10.422

2.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Authors:  Ana Maria Cuervo; Leonidas Stefanis; Ross Fredenburg; Peter T Lansbury; David Sulzer
Journal:  Science       Date:  2004-08-27       Impact factor: 47.728

3.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

4.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  Protein kinase C-mediated suppression of the presynaptic adenosine A1 receptor by a facilitatory metabotropic glutamate receptor.

Authors:  D C Budd; D G Nicholls
Journal:  J Neurochem       Date:  1995-08       Impact factor: 5.372

6.  Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

Authors:  William Dauer; Nikolai Kholodilov; Miquel Vila; Anne-Cecile Trillat; Rose Goodchild; Kristin E Larsen; Roland Staal; Kim Tieu; Yvonne Schmitz; Chao Annie Yuan; Marcelo Rocha; Vernice Jackson-Lewis; Steven Hersch; David Sulzer; Serge Przedborski; Robert Burke; Rene Hen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-10       Impact factor: 11.205

7.  Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.

Authors:  S J Tabrizi; M Orth; J M Wilkinson; J W Taanman; T T Warner; J M Cooper; A H Schapira
Journal:  Hum Mol Genet       Date:  2000-11-01       Impact factor: 6.150

Review 8.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Authors:  Michael J Volles; Peter T Lansbury
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

9.  G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage.

Authors:  M Orth; S J Tabrizi; C Tomlinson; K Messmer; L V P Korlipara; A H V Schapira; J M Cooper
Journal:  Neurochem Int       Date:  2004-10       Impact factor: 3.921

10.  Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.

Authors:  David D Song; Clifford W Shults; Abbyann Sisk; Edward Rockenstein; Eliezer Masliah
Journal:  Exp Neurol       Date:  2004-04       Impact factor: 5.330

View more
  178 in total

Review 1.  The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease.

Authors:  Victor S Van Laar; Sarah B Berman
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

2.  Regulation of complex I by Engrailed is complex too.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2011-09-27       Impact factor: 24.884

Review 3.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 4.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

5.  Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC.

Authors:  Amandine Rovini; Philip A Gurnev; Alexandra Beilina; María Queralt-Martín; William Rosencrans; Mark R Cookson; Sergey M Bezrukov; Tatiana K Rostovtseva
Journal:  Cell Mol Life Sci       Date:  2019-11-23       Impact factor: 9.261

Review 6.  Mechanisms of selective autophagy and mitophagy: Implications for neurodegenerative diseases.

Authors:  Charleen T Chu
Journal:  Neurobiol Dis       Date:  2018-07-17       Impact factor: 5.996

Review 7.  Autophagy in Parkinson's Disease.

Authors:  Xu Hou; Jens O Watzlawik; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

9.  Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.

Authors:  Adam L Orr; Florentine U Rutaganira; Daniel de Roulet; Eric J Huang; Nicholas T Hertz; Kevan M Shokat; Ken Nakamura
Journal:  Neurochem Int       Date:  2017-04-20       Impact factor: 3.921

Review 10.  Parkinson's disease: an update on pathogenesis and treatment.

Authors:  Tom Foltynie; Joshua Kahan
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.